Receptos is a biopharma company developing therapeutic candidates for the treatment of immune and metabolic disorders, including conditions such as relapsing multiple sclerosis and inflammatory bowel disease. In 2013, Receptos raised a $72.8M IPO and began trading on the NASDAQ under the symbol “RCPT.” In 2015, Receptos was acquired by Celgene for $7.2B.


Company Profile

Receptos Logo

Flagship Partners:

  • Doug Cole, Managing Partner